Stock IMMU MENDUS AB
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Mendus AB

Equities

IMMU

SE0005003654

Delayed Nasdaq Stockholm
Other stock markets
 16:16:32 29/04/2024 BST 		5-day change 1st Jan Change
0.465 SEK -2.00% Intraday chart for Mendus AB -5.10% -11.09%
04-16 Mendus AB Announces Board Changes CI
03-27 Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mendus AB Announces Board Changes
Mendus AB Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML
Mendus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mendus AB Announces Clinical Pipeline Update
Mendus AB Appoints Ted Fjällman as Board Member
Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023
Mendus AB and Australasian Leukaemia & Lymphoma Group to Expand Clinical Testing of Vididencel as Maintenance Treatment for AML
Mendus Announces appointment of Nomination Committee for the 2024 Annual General Meeting
Mendus AB Presents Updated Alison Clinical Trial Data for Vididencel in Ovarian Cancer At SITC 2023
Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal
Mendus AB Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data
Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23
Mendus Obtains US FDA's Fast Track Tag for Blood Cancer Therapy
Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia
Mendus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Mendus AB Announces the Publication of Novel Preclinical Data on its Intratumoral Priming Strategy in the Peer-Reviewed Medical Journal 'Frontiers in Immunology
Mendus AB Appoints Lewis Lanier to Scientific Advisory Board
Sweden’s Mendus Receives European Medicines Agency Certification for Cancer Vaccine
Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023
Eurozone's Q1 Recession Weigh on Most EU Markets Thursday
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IMMU Stock
  4. News Mendus AB
  5. Other languages